LOS ALTOS, Calif., Jan. 24, 2019 /PRNewswire/ -- Bioz Inc., a company that has developed the world's first and most comprehensive A.I. search engine for scientific experimentation, today announced an expansion of its advisory board with the addition of Professor Alon Halevy, a world-leading expert in A.I., Machine Learning (ML) and Natural Language Processing (NLP). Professor Halevy, recipient of the Presidential Early Career Award for Scientists and Engineers, is one of the most highly recognized experts in the field of Data Management Systems, with deep expertise in Machine Learning, Named-Entity Recognition (NER), Entity Matching (EM) and Entity Linking (EL).
Professor Halevy spent 10 years at Google, leading Google Research's Structured Data Group. Before joining Google, he was a professor of computer science at the University of Washington in Seattle. Alon founded and sold two startup companies: Nimble Technology, a leader in enterprise IT, which was acquired by Actuate/Open Text Corp, and Transformic, a leader in deep web technology, acquired by Google. Alon holds a Ph.D. in computer science from Stanford University.
"We are very proud to have Professor Alon Halevy as a distinguished member of the Bioz Advisory Board. Alon couples his top-tier A.I. expertise with his hands-on entrepreneurial experience. He is a strong supporter of the Bioz mission of uncovering and structuring objective life science experimentation data, from within tens of millions of published scientific research articles, to empower researchers to make well-informed objective decisions when performing scientific discovery," said Dr. Karin Lachmi, co-founder and chief scientific officer of Bioz.
"It is of tremendous value to have Professor Halevy's many years of startup, academic and enterprise experience on our side. With Professor Halevy, Bioz will further accelerate the development of its evidence-based software and revolutionary deep A.I. technology," said Daniel Levitt, Bioz co-founder and CEO. "Alon's expertise in Machine Learning places Bioz in the enviable position of being the leader in the use of A.I. technology to advance the life science research industry."
"I'm proud to be a member of the prestigious Bioz Advisory Board. Bioz uses the power of A.I. to solve a real problem that ultimately affects every human on Earth," said Professor Alon Halevy. "I have been working in the technology space for over 30 years and find Bioz to be a unique opportunity where I can apply my knowledge to a revolutionary evidence-based decision-making platform that, as we speak, is improving life science research in academia and biopharma."
About Bioz Inc.
Bioz is the world's most advanced A.I. search engine for life science experimentation, empowering scientists in biopharma and academia to accelerate their research towards new discoveries. Bioz guides scientists to the most-validated and cost-effective products to use in their experiments by providing them with evidence-based product recommendations. These recommendations have been reverse-engineered from real-world experiments, as described in over 500 million pages of scientific text from peer-reviewed articles. The result: Bioz.com, the world's most comprehensive source of life science product recommendations and experimentation guidance, covering over 300 million products, 50,000 suppliers, 16 million images and over seven billion protocol conditions and associated techniques, enabling researchers to work faster and more cost-effectively, generating more successful and impactful outcomes. Bioz A.I. was developed by an experienced team of software engineers led by A.I. experts from Microsoft and Google and Nobel Prize winners in chemistry. The technology incorporates proprietary cutting-edge NLP, ML, neural networks, deep learning and domain-specific named-entity recognition, entity matching and entity linking algorithms. What used to take scientists months, now takes them mere minutes with Bioz, 84x times faster than before. By accelerating the pace of experiments, Bioz increases the speed of drug discovery by as much as 56 percent, which translates into billions of research dollars saved. With objectivity, transparency and trustworthiness, Bioz empowers researchers in the top 25 biopharma companies and in more than 12,400 academic institutions in 196 countries.
SOURCE Bioz Inc.